首页> 外文期刊>The international journal of biochemistry and cell biology >EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells
【24h】

EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cells

机译:EZH2受ERK / AKT调控,并靶向整联蛋白alpha2基因以控制结肠癌细胞中的上皮-间质转化和无神经

获取原文
获取原文并翻译 | 示例
           

摘要

Epithelial-Mesenchymal Transition is a good example of cell plasticity. In tumorigenesis, this process has been associated with metastasis. Overexpression of EZH2 has been detected in most malignant human tumors, including colorectal carcinomas. Herein, we provide evidence supporting the idea that oncogenic Epithelial-Mesenchymal Transition in colon cancer cell models is partially controlled by epigenetic factors such as the transcription regulator EZH2. Evaluation of EZH2 mRNA and protein levels revealed overexpression in cell lines with metastatic traits. Analysis of EZH2 mRNA expression was expanded in clinical samples of colon cancer, and high level of EZH2 correlates with appearance of metastasis. Furthermore, inhibition of ERK and AKT pathways in metastatic colon cancer cell lines attenuates EZH2 overexpression. EZH2 promoter analysis illustrates presence of putative AP-1 binding sites and occupancy of transcription factors such as FRA-1 and C-JUN is demonstrated here on EZH2 promoter. Abrogation of EZH2 expression impairs the ability of colon cancer cells to move associated with anoikis in three-dimensional environment. Integrin alpha2 was identified to be a novel EZH2 target by chromatin immunoprecipitation and short hairpin RNA analysis. This study proposes that activation of ERK/AKT pathways and FRA1/C-JUN induce EZH2 overexpression, which results in Integrin alpha2 silencing. Our results show how deregulation of epigenetic factors and mechanisms can affect cancer cell aggressiveness and propose EZH2 as a potential metastasis marker and/or therapeutic target for colorectal cancer treatment. (C) 2012 Elsevier Ltd. All rights reserved.
机译:上皮-间质转化是细胞可塑性的一个很好的例子。在肿瘤发生中,该过程与转移有关。在包括结肠直肠癌在内的大多数恶性人类肿瘤中都检测到了EZH2的过度表达。在这里,我们提供证据支持结肠癌细胞模型中的致癌上皮-间质转化部分受表观遗传因素(例如转录调节因子EZH2)控制的观点。 EZH2 mRNA和蛋白质水平的评估显示具有转移性状的细胞系中过表达。在结肠癌的临床样本中,对EZH2 mRNA表达的分析得到了扩展,并且高水平的EZH2与转移的出现有关。此外,对转移性结肠癌细胞系中ERK和AKT途径的抑制会减弱EZH2的过表达。 EZH2启动子分析表明,假定的AP-1结合位点的存在和EZH2启动子上的转录因子(如FRA-1和C-JUN)的占有率在此处得到证明。 EZH2表达的废止削弱了结肠癌细胞在三维环境中与无神经相关的移动能力。通过染色质免疫沉淀和短发夹RNA分析,整联蛋白alpha2被鉴定为新型EZH2靶标。这项研究表明,ERK / AKT途径和FRA1 / C-JUN的激活诱导EZH2过表达,从而导致整联蛋白α2沉默。我们的结果表明表观遗传因素和机制的失调如何影响癌细胞的侵袭性,并提出EZH2作为结直肠癌治疗的潜在转移标志物和/或治疗靶标。 (C)2012 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号